Karin Pike-Overzet
Karin Pike-Overzet
Leiden University Medical Center
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
SJ Howe, MR Mansour, K Schwarzwaelder, C Bartholomae, M Hubank, ...
The Journal of clinical investigation 118 (9), 2008
New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling
WA Dik, K Pike-Overzet, F Weerkamp, D De Ridder, EFE De Haas, ...
The Journal of experimental medicine 201 (11), 1715-1723, 2005
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia
I Homminga, R Pieters, AW Langerak, JJ de Rooi, A Stubbs, M Verstegen, ...
Cancer cell 19 (4), 484-497, 2011
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy
A Deichmann, S Hacein-Bey-Abina, M Schmidt, A Garrigue, MH Brugman, ...
The Journal of clinical investigation 117 (8), 2225-2232, 2007
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo
K Schwarzwaelder, SJ Howe, M Schmidt, MH Brugman, A Deichmann, ...
The Journal of clinical investigation 117 (8), 2241-2249, 2007
New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy
K Pike-Overzet, M Van Der Burg, G Wagemaker, JJ Van Dongen, ...
Molecular Therapy 15 (11), 1910-1916, 2007
Hematopoietic microRNA-126 protects against renal ischemia/reperfusion injury by promoting vascular integrity
R Bijkerk, C van Solingen, HC de Boer, P van der Pol, M Khairoun, ...
Journal of the American society of nephrology 25 (8), 1710-1722, 2014
T-, B-and NK-lymphoid, but not myeloid cells arise from human CD34+CD38−CD7+ common lymphoid progenitors expressing lymphoid-specific genes
I Hoebeke, M De Smedt, F Stolz, K Pike-Overzet, FJT Staal, J Plum, ...
Leukemia 21 (2), 311-319, 2007
Retroviral vector insertion sites associated with dominant hematopoietic clones mark “stemness” pathways
OS Kustikova, H Geiger, Z Li, MH Brugman, SM Chambers, CA Shaw, ...
Blood 109 (5), 1897-1907, 2007
Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer
K Pike-Overzet, M Rodijk, YY Ng, MRM Baert, C Lagresle-Peyrou, ...
Leukemia 25 (9), 1471-1483, 2011
Ex vivo expansion of hematopoietic stem cells for therapeutic purposes: lessons from development and the niche
P Tajer, K Pike-Overzet, S Arias, M Havenga, FJT Staal
Cells 8 (2), 169, 2019
Aberrant Wnt signaling in leukemia
FJT Staal, F Famili, L Garcia Perez, K Pike-Overzet
Cancers 8 (9), 78, 2016
Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy
K Pike-Overzet, D de Ridder, F Weerkamp, MRM Baert, MMA Verstegen, ...
Leukemia 21 (4), 754-763, 2007
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia
S Rahman, M Magnussen, TE León, N Farah, Z Li, BJ Abraham, KZ Alapi, ...
Blood, The Journal of the American Society of Hematology 129 (24), 3221-3226, 2017
Inflammation and Wnt signaling: target for immunomodulatory therapy?
I Jridi, K Canté-Barrett, K Pike-Overzet, FJT Staal
Frontiers in cell and developmental biology 8, 615131, 2021
Is IL2RG oncogenic in T-cell development?
K Pike-Overzet, D de Ridder, F Weerkamp, MRM Baert, MM Verstegen, ...
Nature 443 (7109), E5-E5, 2006
Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man
RW Hendriks, RGM Bredius, K Pike-Overzet, FJT Staal
Expert opinion on therapeutic targets 15 (8), 1003-1021, 2011
T-sing progenitors to commit
F Weerkamp, K Pike-Overzet, FJT Staal
Trends in immunology 27 (3), 125-131, 2006
Isolation of human and mouse hematopoietic stem cells
YY Ng, MRM Baert, EFE de Haas, K Pike-Overzet, FJT Staal
Genetic Modification of Hematopoietic Stem Cells: Methods and Protocols, 13-21, 2009
Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
FJT Staal, K Pike-Overzet, YY Ng, JJM van Dongen
Leukemia 22 (10), 1849-1852, 2008
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20